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Platelets are blood cells that are critical to hemostasis after vascular injury, and their activation on ruptured atherosclerotic plaque contributes to pathologic thromboses in myocardial infarction and stroke 1 . We previously reported that platelet activation in vitro, in the presence and absence of antiplatelet therapy, is highly heritable 2, 3 . A number of subsequent genome-wide association studies (GWAS) identified several common genetic variants, including those in PEAR1, GP6, ADRA2A, and JMJD1C, which were related to platelet function 4, 5 ; however, the overall proportion of phenotypic variance explained by the identified loci is modest except for GP6 in Jones et al 6 . Furthermore, most variants associated with platelet function, thus far, are noncoding, which has made it challenging to determine the mechanism(s) by which genotype influences phenotype.
Although GWAS have been successful in identifying associations between common genetic variants and platelet function phenotypes 4, 7-9 , they are not well-suited to uncover low frequency (~1-5% minor allele frequency (MAF)) and rare variants (<1% MAF) that may have larger impact on phenotype. These less common variants are of interest when present in coding regions because they have greater potential to modify protein function, providing a clearer biological link between genetic and phenotypic variation. Indeed, by limiting genetic association analyses to exonic variants predicted to alter the gene product, Huffman et al 10 identified several lowfrequency genetic variants in pathways not previously suspected of involvement in hemostasis.
In another recent study, exome sequencing was used to discover exome-wide significant associations in HYAL2 and GSTZ1 with platelet aggregation in the Framingham Heart Study (FHS), with suggestive findings for AR and MAPRE1. 11 The main objective of this study was to identify uncommon and rare genetic variants in coding sequences that are associated with platelet function. To achieve this aim we performed a metaanalysis of Exome Chip results from 3 family-based cohorts of European ancestry, in which platelet aggregation in response to several agonists was well-characterized. We used gene-based and single nucleotide variant (SNV) analyses to discover loci not previously known to be related to platelet function. Significant associations identified in our discovery meta-analysis were then replicated in independent cohorts of European or African American ancestry.
Methods

Description of study populations
GeneSTAR: The Genetic Study of Atherosclerosis Risk (GeneSTAR) is an ongoing, prospective study designed to determine environmental, phenotypic, and genetic causes of premature cardiovascular disease. Participants (n=3,003) were recruited from European-and African-American families (n=891) identified from probands with a premature coronary disease event prior to 60 years of age who were identified at the time of hospitalization in any of 10 Baltimore area hospitals. Apparently healthy siblings of probands and offspring of the siblings and probands were screened for traditional coronary disease and stroke risk factors as part of a 2 week trial of platelet function prior to and following aspirin therapy, 81 mg/day, from 2003-2006 2 . All measures described here were obtained prior to the commencement of aspirin therapy. Exclusion criteria included: 1) the presence of any coronary heart disease or vascular thrombotic event, 2) any bleeding disorder or any hemorrhagic event in the past (stroke, gastrointestinal bleed), 3) use of any anticoagulants or anti-platelet agents (i.e. warfarin, persantin, clopidogrel), 4) chronic or acute nonsteroidal anti-inflammatory agents, including COX-2 inhibitors that could Exome Chip Platelet Agg not be discontinued, 5) recent active gastrointestinal disorder, 6) current pharmacotherapy for a gastrointestinal disorder, 7) pregnancy or risk of pregnancy during the treatment trial, 8) recent menorrhagia, 9) known aspirin intolerance or allergic side effects, 10) serious medical disorders, including autoimmune diseases, renal or hepatic failure, cancer or HIV-AIDS, 11) chronic or acute use of glucocorticosteroid therapy or any drug that may interfere with the measured outcomes, 12) serious psychiatric disorders, and, 13) unable to independently make a decision to participate.
Framingham Heart Study: The Framingham Heart Study (FHS) is a longitudinal family-based study that started to recruit participants of European ancestry in 1948 and now is on its third generation of participants. The Original cohort (first generation) contains 5,209 participants, the Offspring cohort (second generation), began to recruit in 1971, contains 5,124 participants, and the Third Generation cohort, began to recruit in 2002, contains 4,095 participants. In the present study we use data from the Offspring cohort 4 only.
PAPI Study: The Pharmacogenomics of Anti-Platelet Intervention (PAPI) study is a prospective cohort trial examining the relation of genetic variants to platelet function at baseline and in response to clopidogrel and aspirin. Characteristics of the Old Order Amish European cohort that comprise the PAPI study sample have been described previously 12 . Briefly, Amish participants who were over age 20, generally healthy, and agreed to discontinue the use of medications, supplements, and vitamins for at least one week prior to study initiation were eligible for recruitment.
Caerphilly Prospective Study (CaPS): The CaPS study is a sample of unrelated men of European ancestry recruited around the town of Caerphilly, South Wales as described in the past 9 . The ADP phenotype used in this study was collected during phase 2 of CaPS.
A fasting blood sample was drawn from all participants in each study. A complete blood count and cholesterol levels were determined and low-density lipoprotein cholesterol levels was calculated using the Friedewald equation. Hypertension was defined as systolic blood pressure ≥ 140 mm Hg, diastolic blood pressure ≥ 90 mm Hg, and/or use of prescription blood pressure lowering medications. Diabetes and current smoking status were obtained by self-report.
Each of these studies was approved by their local review board (GeneSTAR-Johns Hopkins Institutional Review Board; FHS-Boston University Institutional Review Board; and PAPI-University of Maryland Institutional Review Board) and written informed consent was obtained from all participants. Approval for the CaPS was granted by the South East Wales Local Research Ethics Committee Panel B.
Platelet function tests and phenotype harmonization:
Methods to assess platelet function in vitro are described in detail elsewhere 4, 12 . All 3 discovery cohorts (FHS, GS, PAPI) drew venous blood from fasting participants into citrated (3.2% or 3.8% in FHS) vacutainer tubes. In PAPI, the first 5mL of blood drawn were discarded. In GS, the first 4mL of blood drawn were discarded. All cohorts centrifuged to isolate PRP (180 x g for 15 min in GS and PAPI, 160 x g for 5 min in FHS). After transferring the PRP additional centrifugation was used to isolate PPP (2000 x g for 10 min in GS and PAPI, 2500 x g for 20 min In GS, platelets were stimulated with ADP (2, 5, 10, and 20 µM), equine tendon-derived Type I collagen (1, 2, 5, and 10 µg/ml), epinephrine (2 and 10 µM), or arachidonic acid (1.6 mM). In PAPI, platelets were stimulated with the same agonists and concentrations except that 2 µM epinephrine was not measured. In FHS, the percent aggregation was determined after adding varying concentrations of ADP (0.05, 0.1, 0.5, 1.0, 3.0, 5.0, 10.0 and 15.0 µM) and epinephrine (0.01, 0.03, 0.05, 0.1, 0.5, 1.0, 3.0, 5.0 and 10.0 µM), and with a fixed concentration of arachidonic acid (5 mg/mL). In GS and PAPI, maximum aggregation within 5 min of agonist addition was measured as the percent change in light transmission relative to the PPP control from the same sample. In FHS, maximum percent aggregation was similarly calculated after 4 min for ADP and 5 min for epinephrine. Not all FHS samples were measured at all doses for ADP and epinephrine. Depending on responses to entry dose responses for ADP and epinephrine, additional higher or lower doses were added to reach at least a half-maximal response, or a low dose without a half-maximal response, resulting in different sample sizes at different doses. The lowest dose to create a 50% maximal aggregation (EC 50 ) to ADP or epinephrine was determined for all samples in this fashion. Collagen lag time to 1.9 µmol/L of calf-skin derived Type I collagen was also determined in FHS. As previously noted the distributions of collagen lag times differed somewhat between FHS and GS 4 which may be a factor of differing collagen sources and doses. Platelet aggregation to 0.725 uM ADP (Sigma Aldrich Corp, St. Louis, MO) was determined in CaPS using a Rubel-Renaud coaguloaggregometer at 37C with stirring at 1100 rpm. In CaPS 30 mL of blood was drawn for other uses before fasting blood was drawn into 0.13M sodium citrate vacutainers for the platelet studies. After isolation, PRP was diluted to 300,000 platelets/ul in autologous PPP. Primary and secondary (maximal after ~2-2.5 min) percent aggregation were measured.
Phenotypes were harmonized across studies such that twelve traits were defined for analysis: two low-dose ADP traits, two high-dose ADP traits, two low-dose epinephrine traits, two high-dose epinephrine traits, and four collagen traits. Details are shown in Supplemental Table 1 .
Exome Chip, genotype calls, and quality control (Q/C):
Samples were genotyped using the Illumina HumanExome Bead Chip (GeneSTAR and PAPI used v1.2; FHS used v1.0) and cluster files were created using GenomeStudio software. Genotypes were called using a similar procedure as reported by the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium Exome Chip effort 13 . The total number of variants for analysis was 246,670, including monomorphic variants from autosomes and X chromosome. Quality control procedures were similar to those reported in an Exome Chip meta-analysis of the Blood Cell Consortium 14 . All variants in each study were aligned to the forward strand and an indexed variant call file for subsequent association analyses was generated 
Statistical analysis
Inverse normal transformation was applied to all platelet function traits in each cohort. Traits were adjusted for age, sex, and population stratification-based principal components. In each cohort, the associations of autosomal and X-chromosomal variants with platelet phenotype were analyzed by either raremetalworker (http://genome.sph.umich.edu/wiki/RAREMETALWORKER) or rvtests (http://zhanxw.github.io/rvtests/) 17 with familial correlation accounted for using a linear mixed effects model. The single variant summary statistics and covariance matrices generated from raremetalworker and rvtests were used for meta-analysis. All meta-analyses were performed separately by two independent analysts (MHC and LRY) and the results obtained were identical.
The discovery cohort consisted of Europeans in the GeneSTAR, FHS, and PAPI studies. Metaanalyses were used to discover variants associated with the harmonized platelet phenotypes using both gene-based and SNV approaches. Meta-analyses were performed using RAREMETAL software (http://genome.sph.umich.edu/wiki/RAREMETAL) 18 . Variants were included in metaanalyses if the genotype call rate was ≥95%, Hardy-Weinberg equilibrium p-values >1x10 -7 , and allele frequency among cohorts differed by <0.3. SNV statistics were meta-analyzed using the Cochran-Mantel-Haenszel method. Variable threshold (VT) approach and sequence kernel association tests (SKAT) implemented in RAREMETAL were used for gene-based tests. VT has better power when selected rare variants in a gene have the same effect direction 19 , while SKAT has better power when selected variants have different effect directions 20 . For gene-based tests, we considered only missense, nonsense, and splice site variants with MAF < 0.01. Bonferroni correction was applied to determine genome-wide significant thresholds for gene-based and SNV meta-analyses, where the total number of tests was defined by the number of analyzed genes/variants for each platelet reactivity trait. The thresholds were ~3.3x10 -6 for gene-based and ~4.3x10 -7 for SNV meta-analyses. When a genome-wide significance signal was identified, conditional analyses were conducted (at the meta-analysis level) using RAREMETAL to identify independent signals. The selected significant variants were tested for independence in each round and the procedure was repeated until there was no new signal. Two independent cohorts were used to replicate variants identified from the discovery metaanalyses: 1) CaPS, an all-male population sample of European ancestry (for ADP 0.725 uM in PRP phenotype) 9 , and, 2) the GeneSTAR African American cohort (for all phenotypes). For CaPS, Haplotype Reference Consortium imputed data (based on HRCr1.1 2016 reference panel) were used for replication. SNVs from genes that met Bonferroni significance in the gene-based meta-analysis were selected for replication if the individual SNVs also met nominal significance and the variant was predicted by PolyPhen score 21 and/or SIFT to damage protein structure/function. Consistent with previous methods used to replicate rare variants from locusbased discovery methods, these rare exonic SNVs were selected because of the high probability that these variants had a direct impact on protein function 22, 23 .
Results
Sample characteristics of the discovery and replication cohorts including coronary heart disease risk factors are shown on Table 1 . In general, the study cohorts consisted of middle-aged adults, approximately half of whom were women (except CaPS which is solely male).
QQ plots with genomic control estimates from cohort level GWAS, SNV meta-analyses and gene-based meta-analyses can be found in Supplemental Figure 1 , where the results show no systematic inflation in our meta-analyses.
Gene-based meta-analyses and relation of rare nonsynonymous coding variants to platelet function
Gene-based meta-analyses were used to discover rare exonic variants, in up to 15,478 genes associated with platelet function phenotype. Supplemental Table 2 shows top results from the gene-based association analysis. Only 2 genes (ANKRD26, ABCG1) met Bonferroni-corrected significance for association with platelet function.
Genetic variation in ANKRD26 was significantly associated with low dose ADP-induced platelet aggregation using VT gene-based analyses ( Table 2) . Twelve rare SNVs (cumulative MAF=0.012) in ANKRD26, none of which were present in the PAPI cohort, contributed to the association (β= 0.619; P=7.13x10 -7 ). The MAFs for the 12 SNVs was <0.3% in our European sample, and occurrence of the minor alleles of the 12 SNVs appeared sporadically rather than clustered within families ( Table 2 ). The individual SNVs in ANKRD26 were independent of each other, with maximum pairwise linkage disequilibrium (r 2 ) among them of < 6.58x10 -6 (Supplemental Table 3 ), and together they contributed to an overall positive association with ADP aggregation. For each SNV present in both cohorts, the direction of effect was the same in GeneSTAR and FHS. Five of the variants met nominal significance for association with low dose ADP-induced aggregation ( Table 2) ; however, no single variant met Bonferroni threshold for genome-wide significance in SNV analyses.
We sought to replicate gene-based findings for specific SNVs identified in ANKRD26 gene. Three of the 5 significant SNVs in ANKRD26 were predicted to be possibly or probably damaging by PolyPhen score ( Table 3) . Four of these 5 SNVs were predicted deleterious by 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Exome Chip Platelet Agg SIFT, including the 3 predicted possibly or probably damaging by PolyPhen. Of these 5 SNVs, rs191015656 was significantly associated with platelet aggregation to 0.725 uM ADP in CaPS, and the direction of effect was the same as that observed in GeneSTAR and FHS. Carriers of one copy of the minor allele (A) at rs191015656 had ~17%, ~33%, and ~50% greater aggregation to ADP 3 uM, ADP 2 uM, and ADP 0.725 uM phenotype (in FHS, GeneSTAR, CaPS, respectively) than GG homozygotes ( Fig. 1) . This SNV was not present in the GeneSTAR AA or PAPI cohorts. The SNV causes a Thr181Ile change in the protein and overlaps the ANK5 protein domain according to UniProt annotation. The other SNVs in ANKRD26 did not replicate or were not present in CaPS or GeneSTAR African Americans ( Table 3) .
Three SNVs in ABCG1, each occurring in <0.03% of our sample, contributed to a statistically significant gene-based association with high dose ADP-induced platelet aggregation (β= -2.831; P=1.92x10 -06 ). Pairwise r 2 indicated no linkage disequilibrium among the SNVs. Overall, the variants were associated with reduced ADP aggregation. Two variants met nominal significance for association with ADP aggregation ( Table 2) , but none met genome-wide significant threshold in SNV analyses. We attempted to replicate findings from the 2 SNVs in ABCG1 that met nominal significance; however, neither SNV could be imputed in CaPS with high confidence (for rs151254598 imputation RSqr=0.00683) nor were they present in our GeneSTAR AA cohort ( Table 3) .
SNV meta-analyses and relation of common variants to platelet function
We also meta-analyzed the SNVs present on the Exome Chip to uncover novel variants associated with platelet function. After meta-analysis of variants present in 2 or more of the discovery samples a total of up to 129,094 SNVs were examined. Supplemental Table 4 shows association results for the top 55 SNVs with P<7x10 -06 , excluding the HCP5 and TRIM24 findings discussed below.
The SNV meta-analysis identified 11 variants in 7 chromosomal regions that were genome-wide significantly associated with platelet function phenotypes. All SNVs identified were commonthe MAF for each was >9% in our meta-analysis cohort of European ancestry. Association findings for 5 of the SNVs-rs12566888 in PEAR1, rs1671152 in GP6, rs869244 and rs4545476 near ADRA2A, rs342293 near PIK3CG, and rs10761731 in JMJD1C-confirm our previous reports and are not considered further here (Supplemental Table 5 ) 4 . Three additional SNVs in GP6 were found to be associated with platelet response to collagen (Supplemental Table 4 ) and all were nonsynonymous. However, these SNVs were all in LD (r 2 >0.76) with another SNV in GP6-rs1671152-that we previously reported to be associated with platelet response to collagen 4 .
Several of the SNV association findings with platelet activation phenotypes were novel. rs2263316, which is an intronic variant in a long non-coding RNA called HLA complex P5 (HCP5), was associated with platelet aggregation to ADP ( Table 4 ; P= 3.45x10 -07 ). The alternate allele was related to greater platelet aggregation in the 3 European cohorts included in the metaanalysis. In the CaPS and GeneSTAR African American replication cohorts, the direction of effect for this SNV was the same achieving nominal significance for replication (P=0.044 and 0.039 for CaPS and GeneSTAR African Americans, respectively; Table 4 ). Employing BLUEPRINT Consortium regulatory annotations, we found that rs2263316 intersects with 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Exome Chip Platelet Agg CD34-CD41+CD42+ megakaryocytic cell peaks for hypermethylation and H3K9me3 histone marks, and nearly adjacent to an H3K27me3 peak. The same region is also a DNase hotspot in CD14+CD16-monocytes and overlaps H3K27me3 marks in mesenchymal stem cell bone marrow.
Novel associations with epinephrine-induced platelet aggregation were identified for an intronic variant of TRIM24 (rs1874326) ( Table 4 ). The alternate allele at this locus was associated with reduced platelet aggregation to epinephrine in all 3 European cohorts included in the metaanalyses. However, the finding in European cohorts could not be replicated in GeneSTAR African-Americans individuals and epinephrine-induced platelet aggregation was not assessed in CaPS. The SNV overlaps CD34-CD41+CD42+ megakaryocytic peaks for hypermethylation, H3K27ac and H3K4me1 histones from the BLUEPRINT Consortium.
Discussion
The main finding of this Exome Chip meta-analysis was discovery and replication of an association between a rare coding SNV in ANKRD26 and ADP-induced platelet aggregation. Additional associations of SNVs in ABCG1 and HCP5 with platelet aggregation were also suggested in meta-analyses, with HCP5 findings nominally confirmed in two additional population samples.
We previously performed GWAS to identify several common genetic variants associated with agonist-induced platelet aggregation 4, 5 . The SNV meta-analysis in this study confirmed these previous reports, including the following genetic association findings: PEAR1 with ADP-and epinephrine-induced platelet aggregation; JMJD1C with epinephrine-induced platelet aggregation; PIK3CG with epinephrine-induced platelet aggregation; ADRA2A with epinephrineinduced platelet aggregation; and GP6 with collagen-induced platelet aggregation.
To our knowledge, this is the first report describing an Exome Chip-based study to identify the genetic basis for variability in platelet function. Advantages of an Exome Chip approach over GWAS are greater potential to identify genotype-phenotype associations for rare variants and a closer biological connection between genetic variants and alterations in protein structure/function. The coverage with Exome Chip design provides a different view of the exome than sequencing-based approaches (e.g., with respect to platelet aggregation 11 ). While the Exome Chip has the limitation that it does not find and call de novo variants, exome sequencing may miss variants present on the Exome Chip due to limitations in capture reagent sets and variable site coverage. To enhance our ability to detect biologically relevant rare genetic associations, we limited our gene-based analyses to missense, nonsense, and splice site variants with MAF < 0.01. A similar approach was used to identify novel variants contributing to platelet count and mean platelet volume 14 . Furthermore, we considered the impact of the variant on protein structure/function using PolyPhen 21 and SIFT scores when selecting specific variants for replication.
We identified a strong relation between genetic variation in ANKRD26 and platelet aggregation to ADP in our gene-based meta-analysis. Several rare variants contributed to this overall genebased effect; among these, 5 SNVs were nominally significant in the discovery meta-analysis Exome Chip Platelet Agg and 3 of these 5 were predicted to alter protein structure/function with two prediction programs. One of these SNVs-rs191015656-is a single nucleotide substitution of adenine for guanine, causing isoleucine to be substituted for threonine in the primary protein structure. The Thr181Ile variant we discovered to be associated with increased platelet aggregation is within the fifth Ankyrin repeat domain. Ankyrin repeats are often sites of protein-protein interactions. This specific variant was significantly associated with platelet aggregation to ADP in the CaPS replication cohort, and greater aggregation to ADP was observed for its heterozygotes in all cohorts studied. The magnitude of effect of this genetic variant on aggregation appeared greatest-50% higher compared to GG homozygotes-for the cohort treated with the lowest dose of ADP. Allelic effects on platelet aggregation may be more likely to be unmasked at low doses of agonist where the external stimulus does not overwhelm the endogenous gene effects. This may suggest that future studies seeking to map genetic determinants of platelet aggregation in the general population may want to include assessment of low agonist doses.
The mechanism underlying an association between genetic variation in ANKRD26 and enhanced platelet aggregation to ADP cannot be determined from this study. However, ANKRD26 has previously been reported to be involved in thrombopoiesis. ANKRD26 encodes a 192kD protein that is highly expressed in megakaryocytes (MKs) 24 , and several mutations in the 5' untranslated regulatory region (UTR) are associated with a rare form of familial autosomal dominant thrombocytopenia 25 . Functional studies indicate transcription factors (RUNX1/FLI1) fail to bind the mutated 5' UTR of ANKRD26 and suppress its expression, and its persistence during MK development leads to a reduction in proplatelet formation 26 . It was recently reported that some familial mutations in the 5' UTR of ANKRD26 in subjects with hereditary thrombocytopenia are also associated with reduced platelet aggregation to arachidonic acid and epinephrine 27 . However, a study of 22 independent individuals with 5'UTR mutations found no specific platelet aggregation defect 287 . A recent Exome Chip meta-analysis of >150,000 subjects did not reveal a relation between coding variants in ANKRD26 and platelet count or mean platelet volume 14 and an association with platelet aggregation was not investigated. The role of upstream mutations and coding mutations may be distinct in their effects on platelet maturation, thrombocytopenia and platelet function. Additional studies are needed to elucidate the molecular mechanism for the relation between exonic variation in ANKRD26 and platelet aggregation and the clinical consequences, if any, of this variation.
ABCG1 encodes an ATP-binding cassette (ABC) transporter known to be involved in cellular efflux of high density lipoprotein, suppression of toll-like receptor mediated inflammation, and atherosclerosis 29 . ABC transporters are also known to regulate maturation of hematopoietic progenitor cells and MKs 29 ; however, an association with platelet aggregation has not been reported. Although our gene-based meta-analysis suggested an association between genetic variation in ABCG1 and ADP-induced aggregation, PolyPhen and SIFT predicted both variants we identified to be benign. One of these variants-rs151254598-encoding a glycine to arginine substitution, was associated with a reduction in ADP-induced aggregation in CaPS similar in direction to the discovery cohort; however, we could not impute this rare SNV in CaPS with confidence. Thus, confirmation of this genotype-phenotype association requires additional replication. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Our SNV meta-analysis identified a common intronic variant in HCP5 associated with ADPinduced aggregation. We observed modest replication of this finding in CaPS and the GeneSTAR AA cohorts (P=0.044 and 0.039, respectively). HCP5 encodes a long non-coding RNA within a region that is rich in DNAse I hypersensitivity sites, which are particularly notable in cells of hematopoietic origin. Using BLUEPRINT Consortium data, we show direct overlap of rs2263316 with CD34-CD41+CD42+ megakaryocytic cell peaks for hypermethylation and H3K9me3 histone marks. This SNV is also nearly adjacent to an H3K27me3 peak. These histone marks generally reflect repressive regulatory effects and suggest HCP5 may have specific roles and expression in megakaryocytes. From public gene expression resources, tissues with the highest RNA expression of HCP5 include bone marrow, whole blood, immune cells and spleen. Interestingly, SNVs in HCP5 are associated with disease progression and viral load in patients with HIV infection, suggesting an immunomodulatory role for HCP5 30 ; however, an association with platelet function has not previously been described. Additional studies are required to confirm this association and determine its molecular basis.
Our study has several limitations. We focused on exonic variants, particularly those affecting protein structure/function, to enhance biological plausibility for genotype-phenotype association findings; however, we did not study the molecular mechanism for findings and we cannot exclude that associations observed are due to LD with ungenotyped exonic, intronic, or intergenic variants. Our discovery cohort included ~4,000 subjects of European descent for which we had sufficient power to detect an effect for a rare variant (i.e., occurring with MAF<0.01) explaining 1% of trait variance with 81.3% power ( Supplemental Table 6 ). Thus, we could have missed gene-association findings for variants occurring less frequently or with smaller effect size. We examined genetic associations with platelet function in response to ADP, epinephrine, and collagen. Although we harmonized platelet phenotypes, heterogeneity of phenotypic assessment across studies may have impeded our ability to detect important genotype-phenotype associations. Finally, although platelet aggregation phenotypes have been reported to be associated with thrombotic outcomes (e.g. myocardial infarction) in human subjects 31, 32 , the pathophysiologic relevance of the genotype-phenotype associations identified in this report are yet unknown. Strengths of the study include that it is one of the largest genetic studies of platelet aggregation to date, and the inclusion of two replication samples of diverse origin.
In summary, in a gene-based meta-analysis involving ~4,000 individuals of European ancestry, we identified a novel association between a rare variant in ANKRD26 (rs191015656) and greater platelet aggregation to ADP. A novel association in HCP5 (rs2263316) with greater platelet aggregation to ADP was also identified. Supportive evidence for these associations was provided in independent replication samples. The molecular mechanism and clinical consequences for these gene association findings require further study. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 *Phenotype = ADP low 1; **Phenotype= ADP high 2; MAF= minor allele frequency; Ref= reference allele; Alt= alternate allele; Nhet= number of heterozygotes; Nhetfam= number of families with at least one heterozygote; direction of effect appears in order -GS/FHS/PAPI, X = variant not present in cohort; ***alternate protein isoforms for ANKRD26 and ABCG1 exist that affect some or all of the relative amino acid positions Bold highlight denotes significant replication finding; *see Supplemental Table 1 for metaanalysis phenotype descriptions and mean (SD) in each cohort; **1-sided test statistics are reported since replication required a priori the same direction of effect as discovery; Epinephrine data was not acquired in CaPS and thus unavailable for replication of the TRIM24 signal 
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